Sigma Planning Corp’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-3,775
| Closed | -$385K | – | 1309 |
|
|
2023
Q2 | $385K | Sell |
3,775
-2,545
| -40% | -$259K | 0.01% | 842 |
|
|
2023
Q1 | $575K | Sell |
6,320
-2,975
| -32% | -$270K | 0.02% | 744 |
|
|
2022
Q4 | $353K | Sell |
9,295
-92
| -1% | -$3.5K | 0.01% | 904 |
|
|
2022
Q3 | $236K | Sell |
9,387
-928
| -9% | -$23.3K | 0.01% | 1041 |
|
|
2022
Q2 | $313K | Buy |
+10,315
| New | +$313K | 0.01% | 964 |
|
|
2021
Q4 | – | Sell |
-6,544
| Closed | -$658K | – | 1472 |
|
|
2021
Q3 | $658K | Buy |
6,544
+184
| +3% | +$18.5K | 0.02% | 693 |
|
|
2021
Q2 | $900K | Buy |
6,360
+2,015
| +46% | +$285K | 0.03% | 588 |
|
|
2021
Q1 | $433K | Buy |
4,345
+630
| +17% | +$62.8K | 0.01% | 813 |
|
|
2020
Q4 | $459K | Buy |
+3,715
| New | +$459K | 0.02% | 718 |
|